Document is current
Any future updates will be listed below
-
Authors
Vena, Antonio https://orcid.org/0000-0002-0697-3992
Mezzogori, Laura https://orcid.org/0000-0001-5873-0856
Bassetti, Matteo https://orcid.org/0000-0002-0145-9740
Mastroianni, Antonio https://orcid.org/0000-0002-1641-1491
Greco, Sonia https://orcid.org/0000-0002-1699-3639
Vangeli, Valeria https://orcid.org/0000-0002-4066-7948
López-Cárdenas, Salvador https://orcid.org/0000-0002-6090-033X
Murillo-Pineda, Marina
de la Villa-Martínez, Sofía https://orcid.org/0000-0002-1371-6417
Estévez-Prieto, Agustín
Giacobbe, Daniele Roberto https://orcid.org/0000-0003-2385-1759
Pascale, Renato https://orcid.org/0000-0003-2687-4235
Pontali, Emanuele https://orcid.org/0000-0002-1085-0442
Ruiz-Seco, Maria Pilar https://orcid.org/0000-0003-1050-4520
de Andrés David, Carlos https://orcid.org/0000-0002-3796-8934
Adan, Ivan
Muñoz, Patricia https://orcid.org/0000-0001-5706-5583
,
Tigano, Stefania
Llorca, Alberto Martí
Vatamanu, Oana
Adán, Iván
Hernández, Martha Kestler
Suárez-García, Inés
Ortiz, Jorge Manuel Maza
- License Information
-
More Information
Article History
Received: 29 September 2025
Accepted: 27 January 2026
First Online: 1 March 2026
Declarations
:
: Outside the submitted work, Matteo Bassetti has received funding for scientific advisory boards, travel, and speaker honoraria from Cidara, Gilead, Menarini, MSD, Mundipharma, Pfizer, and Shionogi. Matteo Bassetti is an Editorial Board member of Infectious Diseases and Therapy ; Matteo Bassetti was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Outside the submitted work, Antonio Vena reports personal fees for speaker/advisor from Pfizer Inc, Shionogi, Tillotts Pharma, Menarini, Gilead Italia, Mundipharma, Advanz pharma and MSD. The remaining authors (Laura Mezzogori, Antonio Mastroianni, Sonia Greco, Valeria Vangeli, Salvador López-Cárdenas, Marina Murillo-Pineda, Sofía de la Villa-Martínez, Agustín Estévez-Prieto, Daniele Roberto Giacobbe, Renato Pascale, Emanuele Pontali, Maria Pilar Ruiz-Seco, Carlos de Andrés David, Ivan Adan and Patricia Muñoz) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
: This study was conducted in accordance with Regulation (EU) No. 536/2014, Spanish Royal Decree 957/2020, and the Italian Medicines Agency (AIFA) determination on observational studies, which allow multicenter studies to be conducted on the basis of a single favorable ethical opinion. The study protocol received a favorable opinion from the Ethics Committee of Hospital General Universitario Gregorio Marañón, Madrid, Spain, acting as the promoter Ethics Committee (reference number MICRO.HGUGM.2024–010). All participating institutions conducted the study in accordance with this ethical approval and applicable local requirement.
